Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Reuven J. Schore"'
Publikováno v:
Pediatric Blood & Cancer.
Autor:
Reuven J. Schore, Anne L. Angiolillo, John A. Kairalla, Meenakshi Devidas, Karen R. Rabin, Patrick Zweidler-McKay, Michael J. Borowitz, Brent Wood, Andrew J. Carroll, Nyla A. Heerema, Mary V. Relling, Johann Hitzler, Nina S. Kadan-Lottick, Kelly Maloney, Cindy Wang, William L. Carroll, Naomi J. Winick, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger
Publikováno v:
Leukemia.
Autor:
R. Spencer Tong, Robert B. Gerbing, Todd A. Alonzo, Jeffrey W. Taub, Jim Wang, Lisa Eidenschink Brodersen, Reuven J. Schore, Maureen M. O'Brien, Amy Heerema-McKenney, Jason N. Berman, Shelton A Viola, Michael R. Loken, E. Anders Kolb, Betsy A. Hirsch, Alan S. Gamis, Karen M. Chisholm, Susana C. Raimondi, Nobuko Hijiya, Amy Beckman, Johann Hitzler, Todd E. Druley
Publikováno v:
Blood. 138:2337-2346
Myeloid leukemia in children with Down syndrome (ML-DS) is associated with young age and somatic GATA1 mutations. Because of high event-free survival (EFS) and hypersensitivity of the leukemic blasts to chemotherapy, the prior Children’s Oncology G
Autor:
Nirali Patel, Kathleen Felton, Surajit Bhattacharya, Maria Isabel Almira-Suarez, Augustine Eze, Joyce Turner, Robert Keating, Chima Oluigbo, Reuven J. Schore, Lindsay Kilburn, Roger J. Packer, John S. Myseros, Miriam Bornhorst
Publikováno v:
Journal of neurosurgery. Pediatrics.
OBJECTIVE Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by germline mutations in the TP53 gene. CNS tumors are the fourth most common tumor type in LFS, and recent screening guidelines demonstrate that early tumor detection is
Autor:
Rozalyn L Rodwin, John A Kairalla, Emily Hibbitts, Meenakshi Devidas, Moira K Whitley, Caroline E Mohrmann, Reuven J Schore, Elizabeth Raetz, Naomi J Winick, Stephen P Hunger, Mignon L Loh, Marilyn J Hockenberry, Anne L Angiolillo, Kirsten K Ness, Nina S Kadan-Lottick
Publikováno v:
J Natl Cancer Inst
Background Children with B-acute lymphoblastic leukemia (B-ALL) are at risk for chemotherapy-induced peripheral neuropathy (CIPN). Children’s Oncology Group AALL0932 randomized reduction in vincristine and dexamethasone (every 4 weeks vs 12 weeks d
Autor:
Jyotinder N. Punia, Maurice R.G. O'Gorman, Karen R. Rabin, Richard Sposto, Gerald Wertheim, Viviane C. Cahen, Terri Guinipero, William G. Woods, Reuven J. Schore, Dragos C. Luca, Etan Orgel, Matthew J. Oberley, Jemily Malvar, Alix E. Seif, Sunil S. Raikar
Publikováno v:
Leukemia
The rarity of mixed phenotype acute leukemia (MPAL) has precluded adequate data to incorporate minimal residual disease (MRD) monitoring into therapy. Fluidity in MPAL classification systems further complicates understanding its biology and outcomes;
Autor:
Radha Rohatgi, David A. Jacobsohn, Elizabeth Wells, Reuven J. Schore, Joshua Terao, Anne L. Angiolillo, Evelio Perez, Anant Vatsayan, Birte Wistinghausen, Hema Dave, Challice L. Bonifant, Alexandra Dreyzin
Publikováno v:
Pediatric hematology and oncology. 39(4)
Autor:
Melissa A. Richard, Meenakshi Devidas, Wenjian Yang, John P. Woodhouse, Vilmarie Rodriguez, Johann K. Hitzler, Reuven J. Schore, Anne L. Angiolillo, Michael J. Burke, Wanda L. Salzer, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Jun J. Yang, Philip J. Lupo, Karen R. Rabin
Publikováno v:
Cancer Research. 82:2002-2002
Background: Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL) and are more likely to experience morbidity and mortality from infectious toxicities during treatment compared to those without DS. We sought to
Autor:
Etan Orgel, Olga Militano, Zhiguo Chen, Meenakshi Devidas, Luke Devon Maese, Rachel E. Rau, Anne L. Angiolillo, Jennifer Lynn McNeer, Reuven J. Schore, Elizabeth A. Raetz, Lewis B. Silverman, Naomi J. Winick, Eric Larsen, William L. Carroll, Stuart S Winter, Kimberley Dunsmore, Stephen Hunger, Mignon L. Loh
Publikováno v:
Journal of Clinical Oncology. 40:7000-7000
7000 Background: Asparaginase is integral to pediatric-inspired regimens (PIR) to treat acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA). However, asparaginase-associated toxicities (AAT) often preclude delivery of planned the
Autor:
Abeer Shibli, Martha Glenn, Christopher A. Lazarski, Fahmida Hoq, Boyu Hu, Mimi Mai, Melanie Grant, Maja Stanojevic, Stephanie Ann Bien, Richard F. Ambinder, Catherine M. Bollard, Hema Dave, Reuven J. Schore, Keri Toner, Philp Maglo, Madeline Terpilowski, Patrick J. Hanley
Publikováno v:
Blood Advances
Key Points Multi–TAA-Ts can be generated from patients who have failed prior chemo-immunotherapies for HL.TAA-Ts are safe when given alone and persist long term in responders, and nivolumab increases persistence of TAA-Ts in vivo.
Visual Abstr
Visual Abstr